SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Upgraded by Wall Street Zen

SAB Biotherapeutics (NASDAQ:SABS) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday.

Other research analysts have also recently issued research reports about the stock. Rodman & Renshaw restated a “buy” rating and set a $13.00 price target on shares of SAB Biotherapeutics in a research note on Monday, May 11th. Citigroup initiated coverage on SAB Biotherapeutics in a research note on Friday, May 22nd. They issued a “buy” rating and a $11.00 price objective on the stock. Weiss Ratings reissued a “sell (d+)” rating on shares of SAB Biotherapeutics in a report on Wednesday, July 8th. Leerink Partners raised their target price on SAB Biotherapeutics from $7.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Finally, Zacks Research raised SAB Biotherapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $12.00.

SAB Biotherapeutics Stock Performance

Shares of SAB Biotherapeutics stock opened at $3.51 on Friday. SAB Biotherapeutics has a 52-week low of $1.85 and a 52-week high of $5.15. The firm has a market capitalization of $268.37 million, a PE ratio of -1.66 and a beta of 0.52. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.45 and a quick ratio of 11.45. The company’s fifty day moving average price is $3.69 and its two-hundred day moving average price is $3.84.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.15). On average, analysts expect that SAB Biotherapeutics will post -1.19 EPS for the current year.

Institutional Trading of SAB Biotherapeutics

Several large investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. acquired a new stake in shares of SAB Biotherapeutics during the first quarter worth approximately $29,000. State of Wyoming acquired a new position in shares of SAB Biotherapeutics in the 4th quarter worth approximately $34,000. State Street Corp bought a new stake in SAB Biotherapeutics during the 4th quarter worth approximately $49,000. Fifth Lane Capital LP bought a new stake in SAB Biotherapeutics during the 4th quarter worth approximately $56,000. Finally, ADAR1 Capital Management LLC bought a new stake in SAB Biotherapeutics during the 3rd quarter worth approximately $30,000. 7.82% of the stock is owned by institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.